Needham & Company LLC Reaffirms "Buy" Rating for Cidara Ther

Needham & Company LLC restated their buy rating on shares of Cidara Therapeutics (NASDAQ:CDTX – Free Report) in a research report report published on Friday morning, Benzinga reports. The firm currently has a $3.00 target price on the biotechnology company’s stock. CDTX has been the subject of a number of other reports. HC Wainwright reaffirmed […]

Related Keywords

United States , Jeffrey Stein , Cantor Fitzgerald , Money Concepts Capital Corp , Charles Schwab Investment Management Inc , Needham Company , Cidara Therapeutics Inc , Securities Exchange Commission , Mackenzie Financial Corp , Stratos Wealth Partners , Legacy Wealth Asset Management , Cidara Therapeutics , Free Report , Therapeutics Stock Down , Get Free Report , Exchange Commission , Financial Corp , Schwab Investment Management , Wealth Asset Management , Wealth Partners , Cidara Therapeutics Daily , Nasdaq Cdtx , Cdtx , Medical , Reiterated Rating , Needham Company Llc ,